\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.5}{Submitted Abstracts}{}% 4
\BOOKMARK [0][-]{chapter*.6}{Associated Publications}{}% 5
\BOOKMARK [0][-]{chapter*.7}{Contents}{}% 6
\BOOKMARK [0][-]{chapter*.9}{List of Figures}{}% 7
\BOOKMARK [0][-]{chapter*.10}{List of Tables}{}% 8
\BOOKMARK [0][-]{chapter*.11}{Abbreviations}{}% 9
\BOOKMARK [0][-]{chapter.1}{Cross-tissue comparison of chromatin accessibility, gene expression signature and immunophenotypes in PsA}{}% 10
\BOOKMARK [1][-]{section.1.1}{Introduction}{chapter.1}% 11
\BOOKMARK [2][-]{subsection.1.1.1}{The relevance of cell type and tissue specificity in the study of PsA}{section.1.1}% 12
\BOOKMARK [2][-]{subsection.1.1.2}{Bulk transcriptomic studies in PsA and their limitations}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.3}{Transcriptomics and proteomics at the single cell resolution}{section.1.1}% 14
\BOOKMARK [2][-]{subsection.1.1.4}{The challenges of using a multi-omics approach in the study of complex diseases}{section.1.1}% 15
\BOOKMARK [2][-]{subsection.1.1.5}{Integration of fine-mapping GWAS SNPs and functional data in PsA}{section.1.1}% 16
\BOOKMARK [2][-]{subsection.1.1.6}{Aims}{section.1.1}% 17
\BOOKMARK [1][-]{section.1.2}{Results}{chapter.1}% 18
\BOOKMARK [2][-]{subsection.1.2.1}{PsA patients cohort description and datasets}{section.1.2}% 19
\BOOKMARK [2][-]{subsection.1.2.2}{Immune cellular composition of blood and synovial fluid in the PsA cohort}{section.1.2}% 20
\BOOKMARK [2][-]{subsection.1.2.3}{Differential chromatin accessibility analysis in immune cells reveals differences between SF and PB}{section.1.2}% 21
\BOOKMARK [2][-]{subsection.1.2.4}{Pathway enrichment analysis highlights tissue functional differences in chromatin accessibility}{section.1.2}% 22
\BOOKMARK [2][-]{subsection.1.2.5}{Differential gene expression analysis in paired circulating and synovial immune cells}{section.1.2}% 23
\BOOKMARK [2][-]{subsection.1.2.6}{Characterisation of the CD14+ monocyte heterogeneity in PsA using scRNA-seq}{section.1.2}% 24
\BOOKMARK [2][-]{subsection.1.2.7}{Mass cytometry reveals active cytokine production in CD14+ monocytes.}{section.1.2}% 25
\BOOKMARK [2][-]{subsection.1.2.8}{Prioritisation and interpretation of PsA GWAS SNPs}{section.1.2}% 26
\BOOKMARK [1][-]{section.1.3}{Discussion}{chapter.1}% 27
\BOOKMARK [0][-]{chapter*.58}{Bibliography}{}% 28
